Department of Hepatobiliary Surgery, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, China.
Department of Emergency Medicine, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, China.
Int Immunopharmacol. 2023 May;118:110062. doi: 10.1016/j.intimp.2023.110062. Epub 2023 Mar 23.
Evidence reveals that gastric cancer (GC) is the fifth most common malignancy in humans, and about 770,000 people die from this cancer yearly. It has been reported that new cases and deaths from GC are more common in men than women. Therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, have been common for treating GC. Nevertheless, due to the complications and limitations of these methods, researchers use novel approaches, such as immunotherapeutic or target therapies, to evaluate the effectiveness of treatment in patients with metastatic GC. Studies have shown that monotherapy is usually associated with unpromising outcomes, and combination therapy can be a more practical option for treating metastatic GC. Therefore, to clarify different aspects of chemotherapy and immunotherapy in patients with metastatic GC, this review discussed the achievements and challenges of combining immunotherapeutic methods with chemotherapeutic agents.
证据表明，胃癌（GC）是人类第五种最常见的恶性肿瘤，每年约有 77 万人死于这种癌症。据报道，男性的 GC 新发病例和死亡人数高于女性。手术、化疗和放疗等治疗方法已被广泛用于治疗 GC。然而，由于这些方法的复杂性和局限性，研究人员使用新的方法，如免疫治疗或靶向治疗，来评估转移性 GC 患者的治疗效果。研究表明，单一疗法通常与不理想的结果相关，联合疗法可能是治疗转移性 GC 的更实用的选择。因此，为了阐明转移性 GC 患者化疗和免疫治疗的不同方面，本综述讨论了将免疫治疗方法与化疗药物联合使用的成就和挑战。
